Pub Date : 2025-10-10DOI: 10.1016/j.clinre.2025.102705
{"title":"Retraction notice for several articles","authors":"","doi":"10.1016/j.clinre.2025.102705","DOIUrl":"10.1016/j.clinre.2025.102705","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 9","pages":"Article 102705"},"PeriodicalIF":2.4,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145263690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-10DOI: 10.1016/j.clinre.2025.102713
Vladimir L Cousin, Marine Lys, Ramy Charbel, Jordi Miatello, Pierre Tissières
None.
没有。
{"title":"Loss of Windkessel notch on transcranial doppler, a glancing sign of cerebral hemodynamic alteration","authors":"Vladimir L Cousin, Marine Lys, Ramy Charbel, Jordi Miatello, Pierre Tissières","doi":"10.1016/j.clinre.2025.102713","DOIUrl":"10.1016/j.clinre.2025.102713","url":null,"abstract":"<div><div>None.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 9","pages":"Article 102713"},"PeriodicalIF":2.4,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145279069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-10DOI: 10.1016/j.clinre.2025.102709
Ahmed Abd El Fattah El Bamby , Tamer Abd El Hamid El bedawi , Mohammed Adel Eltomi , Sara Mamdouh Shoeeb , Enji Abd El Wahab Ibrahim
Background
Beta-thalassemia major (β-TM) is a chronic hemoglobinopathy in which improved survival has shifted focus toward long-term complications, notably osteoporosis. The pathogenesis is multifactorial, involving iron overload, bone marrow expansion, endocrine dysfunction, and impaired osteoblast activity. While histomorphometric data highlight reduced bone formation, clinical evidence demonstrates broader and more severe skeletal abnormalities.
Purpose of study
To evaluate osteoporosis in β-TM patients and examine its relationship with serum sclerostin levels.
Methods
This study employed a cross-sectional case-control design. Enrolled 80 individuals diagnosed with β-TM. Participants were equally assigned to two groups: Group I, consisting of β-TM patients, and Group II, composed of healthy controls matched for age and sex.
Results
Serum sclerostin significantly predict osteoporosis among the tested patients (P < 0.001 and AUC = 0.868) at cut-off>0.61 with 80 %sensitivity, 80 %specificity. T score exhibited significantly lower value in beta TM (group I) when compared to control (group II) (P < 0.001). The poorly chelated group exhibited significantly higher T-scores and serum sclerostin levels. In univariate regression, (hemoglobin, transferrin saturation, serum iron, serum ferritin, total iron binding capacity and serum sclerostin) were independent predictors of osteoporosis β TM patients (P < 0.05). In Multivariate regression, serum sclerostin was independent predictor of osteoporosis in β- TM patients (P = 0.02) while weight, height, BMI, WBCs, Platelets, transferrin saturation, serum iron, ferritin were not.
Conclusions
Patients with β-TM exhibit a greater prevalence of osteoporosis and elevated serum sclerostin levels compared to healthy individuals. The increased serum sclerostin in β-TM patients may reflect impaired bone formation and increased bone loss, thus facilitating osteoporosis development.
{"title":"Evaluation of osteoporosis in adult patients with beta-thalassemia major and its relation to serum sclerostin level","authors":"Ahmed Abd El Fattah El Bamby , Tamer Abd El Hamid El bedawi , Mohammed Adel Eltomi , Sara Mamdouh Shoeeb , Enji Abd El Wahab Ibrahim","doi":"10.1016/j.clinre.2025.102709","DOIUrl":"10.1016/j.clinre.2025.102709","url":null,"abstract":"<div><h3>Background</h3><div>Beta-thalassemia major (β-TM) is a chronic hemoglobinopathy in which improved survival has shifted focus toward long-term complications, notably osteoporosis. The pathogenesis is multifactorial, involving iron overload, bone marrow expansion, endocrine dysfunction, and impaired osteoblast activity. While histomorphometric data highlight reduced bone formation, clinical evidence demonstrates broader and more severe skeletal abnormalities.</div></div><div><h3>Purpose of study</h3><div>To evaluate osteoporosis in β-TM patients and examine its relationship with serum sclerostin levels.</div></div><div><h3>Methods</h3><div>This study employed a cross-sectional case-control design. Enrolled 80 individuals diagnosed with β-TM. Participants were equally assigned to two groups: Group I, consisting of β-TM patients, and Group II, composed of healthy controls matched for age and sex.</div></div><div><h3>Results</h3><div>Serum sclerostin significantly predict osteoporosis among the tested patients (P < 0.001 and AUC = 0.868) at cut-off>0.61 with 80 %sensitivity, 80 %specificity. T score exhibited significantly lower value in beta TM (group I) when compared to control (group II) (P < 0.001). The poorly chelated group exhibited significantly higher T-scores and serum sclerostin levels. In univariate regression, (hemoglobin, transferrin saturation, serum iron, serum ferritin, total iron binding capacity and serum sclerostin) were independent predictors of osteoporosis β TM patients (P < 0.05). In Multivariate regression, serum sclerostin was independent predictor of osteoporosis in β- TM patients (P = 0.02) while weight, height, BMI, WBCs, Platelets, transferrin saturation, serum iron, ferritin were not.</div></div><div><h3>Conclusions</h3><div>Patients with β-TM exhibit a greater prevalence of osteoporosis and elevated serum sclerostin levels compared to healthy individuals. The increased serum sclerostin in β-TM patients may reflect impaired bone formation and increased bone loss, thus facilitating osteoporosis development.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 9","pages":"Article 102709"},"PeriodicalIF":2.4,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145274153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-09DOI: 10.1016/j.clinre.2025.102711
Vincent Zimmer , Kristina Welte
{"title":"A strawberry-like polyp in the rectum","authors":"Vincent Zimmer , Kristina Welte","doi":"10.1016/j.clinre.2025.102711","DOIUrl":"10.1016/j.clinre.2025.102711","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 9","pages":"Article 102711"},"PeriodicalIF":2.4,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145257533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-09DOI: 10.1016/j.clinre.2025.102710
Luca Marzi , Federica de Marchi , Francesco Erdini , Chiara Turri , Monica Zoeschg , Andrea Mega
{"title":"Salvage use of tacrolimus in steroid-refractory severe immune hepatitis from vulvar melanoma immunotherapy","authors":"Luca Marzi , Federica de Marchi , Francesco Erdini , Chiara Turri , Monica Zoeschg , Andrea Mega","doi":"10.1016/j.clinre.2025.102710","DOIUrl":"10.1016/j.clinre.2025.102710","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 9","pages":"Article 102710"},"PeriodicalIF":2.4,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145257521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-09DOI: 10.1016/j.clinre.2025.102708
Ting Tong , Xu Hui , Ruizhi Shi , Junfeng Li , Li Xu , Liting Zhang , Kehu Yang
Background and Aim
The efficacy and safety of budesonide combined with azathioprine (AZA) compared to predniso(lo)ne combined with AZA in the treatment of autoimmune hepatitis (AIH) remain uncertain. This study aimed to compare the efficacy and safety of two combination regimens.
Methods
A comprehensive literature search was performed in various databases from database inception to July 2023. The primary outcome was complete biochemical remission rate of AIH. A fixed-effects model was employed when heterogeneity was low, with risk ratios (RR) and 95 % confidence intervals (CIs) reported.
Results
Six studies involving 929 patients were included in the analysis. Among these studies, four were randomized controlled trials (RCTs), while two were cohort studies. The results of the meta-analysis revealed inconsistent findings regarding the complete biochemical remission (CBR) rate between budesonide combined with AZA and predniso(lo)ne combined with AZA in both RCTs and cohort studies. (RCT: RR=1.45, 95 % CI: 1.24 to 1.68; cohort study: RR=0.86, 95 % CI: 0.57 to 1.28). The meta-analysis revealed that the combination of budesonide and AZA was associated with a reduced occurrence of adverse events (AEs) (RCT: RR=0.49, 95 % CI: 0.35 to 0.69; cohort study: RR=0.61, 95 % CI: 0.43 to 0.88) and steroid-related AEs (RCT: RR=0.51, 95 % CI: 0.35 to 0.74; cohort study: RR=0.64, 95 % CI: 0.44 to 0.95).
Conclusion
The combination of budesonide and AZA may offer potential advantages in terms of efficacy and safety for populations with less severe liver damage or lower ALT/AST levels, although the certainty of evidence is currently low to very low.
{"title":"The efficacy and safety of budesonide combined with azathioprine versus predniso(lo)ne combined with azathioprine for autoimmune hepatitis: A systematic review and meta-analysis","authors":"Ting Tong , Xu Hui , Ruizhi Shi , Junfeng Li , Li Xu , Liting Zhang , Kehu Yang","doi":"10.1016/j.clinre.2025.102708","DOIUrl":"10.1016/j.clinre.2025.102708","url":null,"abstract":"<div><h3>Background and Aim</h3><div>The efficacy and safety of budesonide combined with azathioprine (AZA) compared to predniso(lo)ne combined with AZA in the treatment of autoimmune hepatitis (AIH) remain uncertain. This study aimed to compare the efficacy and safety of two combination regimens.</div></div><div><h3>Methods</h3><div>A comprehensive literature search was performed in various databases from database inception to July 2023. The primary outcome was complete biochemical remission rate of AIH. A fixed-effects model was employed when heterogeneity was low, with risk ratios (RR) and 95 % confidence intervals (CIs) reported.</div></div><div><h3>Results</h3><div>Six studies involving 929 patients were included in the analysis. Among these studies, four were randomized controlled trials (RCTs), while two were cohort studies. The results of the meta-analysis revealed inconsistent findings regarding the complete biochemical remission (CBR) rate between budesonide combined with AZA and predniso(lo)ne combined with AZA in both RCTs and cohort studies. (RCT: RR=1.45, 95 % CI: 1.24 to 1.68; cohort study: RR=0.86, 95 % CI: 0.57 to 1.28). The meta-analysis revealed that the combination of budesonide and AZA was associated with a reduced occurrence of adverse events (AEs) (RCT: RR=0.49, 95 % CI: 0.35 to 0.69; cohort study: RR=0.61, 95 % CI: 0.43 to 0.88) and steroid-related AEs (RCT: RR=0.51, 95 % CI: 0.35 to 0.74; cohort study: RR=0.64, 95 % CI: 0.44 to 0.95).</div></div><div><h3>Conclusion</h3><div>The combination of budesonide and AZA may offer potential advantages in terms of efficacy and safety for populations with less severe liver damage or lower ALT/AST levels, although the certainty of evidence is currently low to very low.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 9","pages":"Article 102708"},"PeriodicalIF":2.4,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145257573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-06DOI: 10.1016/j.clinre.2025.102707
Jiuliang Jiang , Pingping Yang , Guimin Hou
We present the case of a patient with abdominal follicular dendritic cell sarcoma (FDCS) with liver metastasis, a tumor with an extremely low prevalence. The preoperative diagnosis of FDCS remains challenging due to the rarity of this disease. Despite the complete surgical removal of the lesion, the risk of local recurrence after surgery for FDCS remains high. Furthermore, adjuvant radiotherapy and chemotherapy have been demonstrated to have no significant impact on the overall survival of the patient. A pan-cancer panoramic gene test was conducted on pathological specimens from patients, and the results indicated the presence of a class II variant, namely a reduction in the copy number of the CDKN2A gene. Piperacillin may prove to be a targeted drug with the potential to influence patient prognosis. During the three-month follow-up period following asymptomatic discharge, the patient's condition remained stable. The genetic testing of surgical resection specimens to determine subsequent treatment plans may represent a future treatment strategy.
{"title":"An unusual follicular dendritic cell sarcoma with liver metastasis","authors":"Jiuliang Jiang , Pingping Yang , Guimin Hou","doi":"10.1016/j.clinre.2025.102707","DOIUrl":"10.1016/j.clinre.2025.102707","url":null,"abstract":"<div><div>We present the case of a patient with abdominal follicular dendritic cell sarcoma (FDCS) with liver metastasis, a tumor with an extremely low prevalence. The preoperative diagnosis of FDCS remains challenging due to the rarity of this disease. Despite the complete surgical removal of the lesion, the risk of local recurrence after surgery for FDCS remains high. Furthermore, adjuvant radiotherapy and chemotherapy have been demonstrated to have no significant impact on the overall survival of the patient. A pan-cancer panoramic gene test was conducted on pathological specimens from patients, and the results indicated the presence of a class II variant, namely a reduction in the copy number of the CDKN2A gene. Piperacillin may prove to be a targeted drug with the potential to influence patient prognosis. During the three-month follow-up period following asymptomatic discharge, the patient's condition remained stable. The genetic testing of surgical resection specimens to determine subsequent treatment plans may represent a future treatment strategy.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 9","pages":"Article 102707"},"PeriodicalIF":2.4,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-03DOI: 10.1016/j.clinre.2025.102706
Amine Antonin Alam, Nadia Fathallah, Manuel Aubert, Paul Benfredj, Elise Pommaret, Vincent de Parades
Background
Management of first-time perianal abscesses remains controversial. While the French school of proctology systematically investigates fistulas, other approaches advocate simple incision, given that over 60 % of patients do not develop recurrence. The role of post-incision antibiotic therapy is also debated. This study aimed at evaluating our department’s approach to managing first perianal abscesses and identifying predictive factors for recurrence.
Methods
We retrospectively included all patients presenting in 2019 with a first perianal abscess treated by incision under local anesthesia, with or without antibiotic therapy post-incision. Patients with evident fistulas underwent surgery. Recurrence was defined as a new abscess or purulent opening. The primary outcome was the rate of patients requiring fistula surgery and/or experiencing abscess recurrence; secondary outcomes included identification of recurrence predictors.
Results
Among the 336 patients who consulted for an abscess, 109 were included. Among 109 patients (mean age 43 ± 13 years; 74 % male), 55 had incision alone, and 54 underwent fistula surgery. The mean follow-up for patients with incision alone was approximately 30 months, during which 18 % (10 patients) experienced abscess recurrence. Univariate logistic regression analysis revealed smoking and absence of antibiotic therapy post-incision as predictive of recurrence with (OR 0.44) were predictive of recurrence. Gender, age, BMI, diabetes, Crohn's disease, HIV infection, prior NSAID use, and abscess location were not predictive. Multivariate analysis was not conducted due to insufficient data.
Conclusion
This study demonstrates that 41 % of patients who underwent incision for a first perianal abscess did not experience recurrence during the follow-up period. Additionally, the administration of antibiotic therapy post-incision was associated with a reduced likelihood of recurrence. However, randomized trials are warranted to validate these findings and specify the optimal antibiotic regimen.
{"title":"Does antibiotic therapy for anal abscess reduce the risk of fistula surgery? A retrospective study","authors":"Amine Antonin Alam, Nadia Fathallah, Manuel Aubert, Paul Benfredj, Elise Pommaret, Vincent de Parades","doi":"10.1016/j.clinre.2025.102706","DOIUrl":"10.1016/j.clinre.2025.102706","url":null,"abstract":"<div><h3>Background</h3><div>Management of first-time perianal abscesses remains controversial. While the French school of proctology systematically investigates fistulas, other approaches advocate simple incision, given that over 60 % of patients do not develop recurrence. The role of post-incision antibiotic therapy is also debated. This study aimed at evaluating our department’s approach to managing first perianal abscesses and identifying predictive factors for recurrence.</div></div><div><h3>Methods</h3><div>We retrospectively included all patients presenting in 2019 with a first perianal abscess treated by incision under local anesthesia, with or without antibiotic therapy post-incision. Patients with evident fistulas underwent surgery. Recurrence was defined as a new abscess or purulent opening. The primary outcome was the rate of patients requiring fistula surgery and/or experiencing abscess recurrence; secondary outcomes included identification of recurrence predictors.</div></div><div><h3>Results</h3><div>Among the 336 patients who consulted for an abscess, 109 were included. Among 109 patients (mean age 43 ± 13 years; 74 % male), 55 had incision alone, and 54 underwent fistula surgery. The mean follow-up for patients with incision alone was approximately 30 months, during which 18 % (10 patients) experienced abscess recurrence. Univariate logistic regression analysis revealed smoking and absence of antibiotic therapy post-incision as predictive of recurrence with (OR 0.44) were predictive of recurrence. Gender, age, BMI, diabetes, Crohn's disease, HIV infection, prior NSAID use, and abscess location were not predictive. Multivariate analysis was not conducted due to insufficient data.</div></div><div><h3>Conclusion</h3><div>This study demonstrates that 41 % of patients who underwent incision for a first perianal abscess did not experience recurrence during the follow-up period. Additionally, the administration of antibiotic therapy post-incision was associated with a reduced likelihood of recurrence. However, randomized trials are warranted to validate these findings and specify the optimal antibiotic regimen.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 9","pages":"Article 102706"},"PeriodicalIF":2.4,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145231443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-29DOI: 10.1016/j.clinre.2025.102702
Haoxiang Zhu , Jiesen Yu , Jieren Luo , Zihao Cai , Lujin Li , Qingshan Zheng
Background and Aim
Drug development for non-alcoholic fatty liver disease (NAFLD) is frequently hampered by the poor translation of preclinical findings into clinical efficacy. To address this critical challenge, we developed a quantitative cross-species model designed to predict human clinical outcomes from efficacy data in mouse models.
Methods
We performed a model-based meta-analysis (MBMA) of 18 NAFLD drugs, integrating data from published clinical trials with corresponding preclinical mouse studies identified through a systematic search of the Embase and PubMed databases. Using the change in alanine aminotransferase (ΔALT) as the primary biomarker, we constructed an exponential model to define the relationship between ALT reduction in mice and the placebo-corrected response in humans (ΔΔALT). The model's predictive performance was then externally validated using an independent dataset from a study of Linggui Zhugan Tang (LGZGT).
Results
The analysis yielded a robust exponential model, which revealed that a reduction in mouse ΔALT of at least 53.3 U/L is required for a drug to show superiority over placebo in human trials. A more substantial decrease of 128.3 U/L in mice predicted a clinical efficacy exceeding that of Resmetirom, the first FDA-approved therapy for this condition. The model's predictive power was successfully confirmed through external validation with the LGZGT data.
Conclusions
This study developed a cross-species efficacy model from NAFLD clinical and mouse data, revealing an exponential relationship between human and mouse ALT levels. This provides quantitative thresholds for preclinical screening to improve drug development success rates.
{"title":"Development of a cross-species model to predict clinical outcomes based on efficacy in mouse models of non-alcoholic fatty liver disease","authors":"Haoxiang Zhu , Jiesen Yu , Jieren Luo , Zihao Cai , Lujin Li , Qingshan Zheng","doi":"10.1016/j.clinre.2025.102702","DOIUrl":"10.1016/j.clinre.2025.102702","url":null,"abstract":"<div><h3>Background and Aim</h3><div>Drug development for non-alcoholic fatty liver disease (NAFLD) is frequently hampered by the poor translation of preclinical findings into clinical efficacy. To address this critical challenge, we developed a quantitative cross-species model designed to predict human clinical outcomes from efficacy data in mouse models.</div></div><div><h3>Methods</h3><div>We performed a model-based meta-analysis (MBMA) of 18 NAFLD drugs, integrating data from published clinical trials with corresponding preclinical mouse studies identified through a systematic search of the Embase and PubMed databases. Using the change in alanine aminotransferase (ΔALT) as the primary biomarker, we constructed an exponential model to define the relationship between ALT reduction in mice and the placebo-corrected response in humans (ΔΔALT). The model's predictive performance was then externally validated using an independent dataset from a study of Linggui Zhugan Tang (LGZGT).</div></div><div><h3>Results</h3><div>The analysis yielded a robust exponential model, which revealed that a reduction in mouse ΔALT of at least 53.3 U/L is required for a drug to show superiority over placebo in human trials. A more substantial decrease of 128.3 U/L in mice predicted a clinical efficacy exceeding that of Resmetirom, the first FDA-approved therapy for this condition. The model's predictive power was successfully confirmed through external validation with the LGZGT data.</div></div><div><h3>Conclusions</h3><div>This study developed a cross-species efficacy model from NAFLD clinical and mouse data, revealing an exponential relationship between human and mouse ALT levels. This provides quantitative thresholds for preclinical screening to improve drug development success rates.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 9","pages":"Article 102702"},"PeriodicalIF":2.4,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-29DOI: 10.1016/j.clinre.2025.102701
Arthur Marichez , Nour Aldajani , Catherine Fleureau , Jean-Philippe Adam , Brigitte Le Bail , Hugo Madar , Loïc Sentilhes , Laurence Chiche
Background
The discovery of a liver mass during pregnancy requires careful etiological assessment.A 29-year-old woman was diagnosed with a 17-cm inflammatory hepatocellular adenoma at 24-weeks of gestation. Given the high risk of spontaneous rupture and bleeding,a multidisciplinary team opted for a right hepatectomy at 26-weeks. To maintain stable maternal hemodynamics and avoid fetal hypoperfusion, a veno-venous cavo-caval bypass was established, allowing liver resection under total vascular exclusion without blood pressure fluctuations. The procedure was uneventful and a healthy child was delivered at term. The use of cavo-caval bypass offers a protective strategy to stabilize maternal circulation and preserve fetal well-being during major hepatectomy.
{"title":"Protecting the fetus during hepatic surgery in pregnancy: the role of cavo-caval bypass","authors":"Arthur Marichez , Nour Aldajani , Catherine Fleureau , Jean-Philippe Adam , Brigitte Le Bail , Hugo Madar , Loïc Sentilhes , Laurence Chiche","doi":"10.1016/j.clinre.2025.102701","DOIUrl":"10.1016/j.clinre.2025.102701","url":null,"abstract":"<div><h3>Background</h3><div>The discovery of a liver mass during pregnancy requires careful etiological assessment.A 29-year-old woman was diagnosed with a 17-cm inflammatory hepatocellular adenoma at 24-weeks of gestation. Given the high risk of spontaneous rupture and bleeding,a multidisciplinary team opted for a right hepatectomy at 26-weeks. To maintain stable maternal hemodynamics and avoid fetal hypoperfusion, a veno-venous cavo-caval bypass was established, allowing liver resection under total vascular exclusion without blood pressure fluctuations. The procedure was uneventful and a healthy child was delivered at term. The use of cavo-caval bypass offers a protective strategy to stabilize maternal circulation and preserve fetal well-being during major hepatectomy.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 9","pages":"Article 102701"},"PeriodicalIF":2.4,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：